Allurion Technologies Holdings Inc. has released its preliminary, unaudited financial results for the second quarter of 2025, reporting revenue of approximately $3 million. The company also recorded an operating loss of about $7 million, showing an improvement compared to the operating loss of $9.3 million in the second quarter of 2024. This reduction in operating loss is partly attributed to a 50% decrease in operating expenses year-over-year. In strategic developments, Allurion is focusing on its R&D and clinical pipelines, emphasizing combination therapy and expanding its strategic distribution partnerships. The company has reported that clinics piloting the combination approach as part of a comprehensive obesity management program experienced a 20% growth in the second quarter of 2025 compared to the first quarter of the same year. Allurion has launched several initiatives, including a signed term sheet with a strategic partner to enhance its ex-US distribution and R&D pipeline. This includes the potential joint development of a novel, GLP-1 drug-eluting intragastric balloon. Additionally, the company has submitted a study protocol to European Institutional Review Boards for approval, focusing on combining the Allurion Program with low-dose GLP-1 for weight loss while maintaining muscle mass. Enrollment for this study is expected to begin within the year.